In this issue: five end of the year SPARC stories, eight topline findings from the coalition health score card, in-country strategy labs and the all COMPASS strategy lab.
COMPASS Africa Newsletter (February 2023)
Year End Newsletter
Re: Draft Recommendation Statement and Draft Evidence Review: Pre-Exposure Prophylaxis for the Prevention of HIV Infection
AVAC submits comment and response to the United States Preventative Services Task Force (USPSTF) Draft Recommendation statement for PrEP. The USPSTF recommended an “A” Grade for PrEP that includes CAB for PrEP.
Correlations between Oral Pre-Exposure Prophylaxis (PrEP) Initiations and Policies that Enable the Use of PrEP to Address HIV Globally
This article from PLoS Global Public Health presents the results of an analysis examining whether policies enabling broad PrEP eligibility, HIV self-testing, and lowered age of consent to HIV testing and treatment services are correlated with PrEP uptake.
AVAC Comments to FDA in Support of PrEP Approval
Comments delivered to the FDA’s Antiviral Drugs Advisory Committee (AVDAC) Meeting by Mitchell Warren, Executive Director, AVAC.
Future Prospects for New Vaccines Against Sexually Transmitted Infections
This review provides an update on the need, development status, and important next steps for advancing development of vaccines against sexually transmitted infections (STIs), including herpes simplex virus (HSV), Neisseria gonorrhoeae (gonorrhea), Chlamydia trachomatis (chlamydia), and Treponema pallidum (syphilis).
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
The results of HPTN 083, a trial evaluating the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW), in the New England Journal of Medicine.
Enhancing HIV Prevention with Injectable Preexposure Prophylaxis
Quarraisha Abdool Karim, Ph.D. writes about the results of HPTN 083 and the implications of long-acting injectable of PrEP with cabotegravir in the New England Journal of Medicine.
Calling on the Biden Administration to Scale Up mRNA Vaccine Manufacturing Capacity
This joint letter calls on the Biden Administration to rapidly scale up mRNA vaccine manufacturing capacity to reach approximately 4 billion people by the end of 2021.
Research Work Group of the Federal AIDS Policy Partnership’s response to the NIH Request for Information (RFI)
This letter is the Research Work Group of the Federal AIDS Policy Partnership’s response to the NIH Request for Information (RFI) inviting comments and suggestions to advance and strengthen racial equity, diversity and inclusion in the biomedical research workforce and advance health disparities and health equity research.
Public Comment from Mitchell Warren, Executive Director, AVAC At the Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting
Comments made by Mitchell Warren to the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting on October 22, 2020 about COVID-19 vaccine development and use authorization.